AK112, Carboplatin, Paxlitaxel

DRUG2 trials

Sponsors

Akeso, Shuangyue Liu

Conditions

Advanced Squamous Non Small Cell Lung CancerBreast Cancer - Female

Phase 2

Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC

Not yet recruitingNCT07103447

Shuangyue LiuBreast Cancer - Female

Start: 2025-09-10End: 2028-12-31Target: 54Updated: 2025-08-05

Phase 3

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Active, not recruitingNCT05840016

AkesoAdvanced Squamous Non Small Cell Lung Cancer

Start: 2023-08-17End: 2026-12-31Updated: 2025-05-02

Related Papers

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.

Journal of Clinical Oncology2026-06-03

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

2026-05-31

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.

2025-10-192 citations

Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2024-04-0147 citations